Agios Pharmaceuticals is a biopharmaceutical company focused on improving patients' lives in the field of cellular metabolism and adjacent areas of biology, with the goal of creating molecule medicines for genetically defined diseases (GDD). The lead product in its GDD, portfolio, PYRUKYND® (mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the potential treatment of hemolytic anemias. Co. is evaluating PYRUKYND® for the treatment of a- and B-thalassemia and sickle cell disease (SCD). Co. is also developing AG-946, a PK activator, for the potential treatment of hemolytic anemias and other indications, including SCD. We show 37 historical shares outstanding datapoints in our AGIO shares outstanding history coverage, used to compute AGIO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AGIO market cap history over the course of time is important for investors
interested in comparing AGIO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AGIO versus a peer is one thing; comparing
AGIO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AGIO can fluctuate over the course of history.
With this page we aim to empower investors researching AGIO by allowing them to research the AGIO market cap history. |
Free AGIO Email Alerts:
Video: The Importance of Market Cap
